2|0|Public
50|$|Oxford BioMedica {{entered a}} global {{development}} and <b>commercialisation</b> <b>agreement</b> for TroVax in March 2007 with sanofi-aventis. There are many aspects to this agreement including co-funding the ongoing TRIST study and funding all other research, development, regulatory and commercialisation activities.|$|E
5000|$|... 2009â€”Syngene {{partners}} with Sapient Discovery to expand integrated drug discovery offerings; Syngene and DuPont Crop Protection Forge Alliance Partnership; Bristol-Myers Squibb and Syngene open new R&D facility at Biocon Park; Biocon launches BASALOGTM - long lasting basal insulin for Type 1 & Type 2 Diabetics; Biocon inks partnership with ISB {{to launch the}} Biocon Cell for Innovation Management; Announces strategic collaboration with Mylan to enter the global generic biologics market; Biocon and Amylin Pharmaceuticals enter into a global development and <b>commercialisation</b> <b>agreement</b> for a novel peptide hybrid.|$|E

